Clinical trials: Hematologic and Lymphocytic Disorder
B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma
- Trial name
- NCT00010192
- Testing
- rituximab, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
This randomized phase III trial compares bortezomib, dexamethasone, and lenalidomide with bortezomib and dexamethasone to see how well they work in treating patients with multiple myeloma previously treated with dexamethasone.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00522392
- Testing
- bortezomib, lenalidomide, dexamethasone
- Where
- 276 sites in United States, South Africa
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Anemia
TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta
To describe the time course of hemoglobin concentration in EU hemodialysis patients switched from methoxy polyethylene glycol-epoetin beta (PEG epoetin beta; Mircera) to darbepoetin alfa (Aranesp).
- Trial name
- TRANSFORM (NCT01997892)
- Where
- 32 sites in Belgium, France and 5 more
- Volunteers
- 1,027 people
- Sponsor
- Amgen
Hematological Malignancies
Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)
This is study is for patients that have been diagnosed with high-risk hematological malignancies. The main purpose of this study is to confirm previously published results of stem cell transplantation with reduced intensity…
- Trial name
- NCT01139164
- Testing
- Regimen A, Regimen B, Regimen C
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Medical University of South Carolina
Monoclonal Gammopathy, Tuberculosis
Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis
The purpose of this study is to determine whether the monoclonal protein in patients with tuberculosis and monoclonal gammopathy has anti-tuberculous activity, and whether genes coding their monoclonal proteins show…
- Trial name
- NCT00173264
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Esophageal Cancer, Intensity-modulated Radiation Therapy
The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients
The goal of this interventional study is to explore the protective effect of prophylactic TPO combined with bone marrow sparing (BMS)-IMRT in patients with esophageal cancer undergoing concurrent chemoradiotherapy.
- Conditions
- Esophageal Cancer, Intensity-modulated Radiation Therapy, Concurrent Chemoradiotherapy, Thrombocytopenia
- Trial name
- NCT05944809
- Testing
- rhTPO
- Where
- China
- Volunteers
- 32 people
- Sponsor
- JIANYANG WANG
Leukemia, Lymphoma
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
The goal of this clinical research study is to learn if researchers can successfully and safely give HSCT patients an infusion of white blood cells (called T-cells) that have been genetically changed.
- Trial name
- NCT01497184
- Testing
- HSCT, DLI
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- M.D. Anderson Cancer Center
Thrombocytopenia, Alloimmune Platelet Refractoriness
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Background: Platelets are tiny cells in the blood that help stop bleeding. Thrombocytopenia happens when people do not have enough normal platelets.
- Trial name
- NCT02298933
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
This phase I trial is studying the side effects and best dose of temsirolimus when given together with dexamethasone in treating patients with recurrent or refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00693433
- Testing
- dexamethasone, temsirolimus, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
RATIONALE: Chemotherapy, such as busulfan, melphalan, and thiotepa, may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow.
- Trial name
- NCT00238433
- Testing
- filgrastim, busulfan, melphalan
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Trial name
- NCT07321652
- Testing
- Zanubrutinib, Sonrotoclax, Computed Tomography
- Where
- 261 sites in United States
- Volunteers
- 466 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Myelodysplastic Syndrome (MDS)
Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome
This study will test whether certain patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) can safely be vaccinated with two peptide vaccines derived from proteins called…
- Trial name
- NCT00270452
- Testing
- WT1 and PR1 Peptide Vaccine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Idiopathic Thrombocytopenic Purpura
Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura
The investigators are trying to investigate the coagulation status of idiopathic (immune) thrombocytopenic purpura patients by measuring the platelet count, coagulation battery, von Willebrand factor level, thromboelastography.
- Trial name
- NCT01571349
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Multiple Myeloma
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
This is a randomized, double-blind, multicenter trial，parallel control designed to evaluate treatment with pomalidomide + QL2109 + dexamethasone compared with pomalidomide + DARZALEX FASPRO® + dexamethasone in the participants…
- Trial name
- NCT06742138
- Testing
- QL2109, Pomalidomide, Dexamethasone
- Volunteers
- 284 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Leukemia, Leukemia, Myeloid
Breath Analysis for the Detection of Invasive Fungal Infections
Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Lymphoblastic, Neutropenia
- Trial name
- REDEFINE (NCT06537726)
- Testing
- Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
- Where
- Switzerland
- Volunteers
- 130 people
- Sponsor
- University of Zurich
Polycythemia Vera (PV), Essential Thrombocythemia (ET)
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of clonal hematological malignancies that are characterized by chronic myeloproliferation, splenomegaly, different degrees of bone marrow…
- Trial name
- Ruxo-BEAT (NCT02577926)
- Testing
- Ruxolitinib, BAT
- Where
- 23 sites in Germany
- Volunteers
- 207 people
- Sponsor
- RWTH Aachen University
Multiple Myeloma, Venous Thromboembolism
Thrombosis in Patients With Multiple Myeloma in an University Medical Center
Main research question: What is the present venous thrombosis incidence and what are the current practices of prescribing thromboprophylaxis in patients with multiple myeloma (MM)? Design: The present study is a retrospective…
- Conditions
- Multiple Myeloma, Venous Thromboembolism, Arterial Thromboembolism
- Trial name
- THRIMM (NCT05541978)
- Testing
- Multiple myeloma
- Where
- Netherlands
- Volunteers
- 140 people
- Sponsor
- Catalina Codreanu
Multiple Myeloma, Myeloma
Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
Myeloma is the second most common type of blood cancer in the United States. Myeloma most commonly affects older adults. While some younger individuals do get myeloma, the average age when people are first diagnosed with myeloma…
- Conditions
- Multiple Myeloma, Myeloma, Disability Physical, Disabilities Multiple
- Trial name
- NCT04999085
- Testing
- Supportive care interventions
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Myeloid Leukemia
Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia
Treatment of acute myeloid leukemia (AML) consists in two main phases: induction and consolidation. Standard chemotherapy combination for induction treatment associates cytarabine (AraC), a nucleoside analog, and an anthracycline…
- Trial name
- NUCLARA (NCT03234985)
- Testing
- Biological analyses
- Where
- France
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
RATIONALE: Taking part in a clinical trial may help children with cancer receive more effective treatment. PURPOSE: Determine why patients who are eligible for protocols made available through the Pediatric Oncology Group do not…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia
- Trial name
- NCT00002485
- Testing
- psychosocial assessment and care
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 359 people
- Sponsor
- Children's Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.